This website is intended for healthcare professionals only.
TREATING mPaCa PATIENTS: FROM SCIENTIFIC EVIDENCE TO REAL CLINICAL PRACTICE
Professor Teresa Macarulla MD, PhD Head of the Gastrointestinal Cancer Program Unit Vall d’Hebron, University Hospital - Barcelona, Spain
This webinar highlights the importance of considering both patient wishes and clinician experience when making treatment decisions in metastatic pancreatic cancer (mPaCa). The case study of a patient diagnosed with mPaCa is presented throughout the webinar to offer a more concrete example of how a patient's feeling and wishes, as well as the clinician's perspective, can be incoporated into their treatment plan.
Key points covered
This webinar highlights the importance of factoring in patient and clinician perspective in mPaCa treatment decision.
Beyond evidence and guidelines, treatment decisions in mPaCa need to be based on the patient feelings and wishes, and clinician experience
Sequential treatment algorithms must also be considered to give patients the best available treatments
While both FOLFIRINOX and nab-Paclitaxel + gemcitabine are standards-of-care 1L in mPaCa, only Nal-IRI+ 5-FU/LV post-gemcitabine is approved for 2L
Webinar Replay
Featured Speaker
Prof. Teresa Macarulla
Teresa Macarulla, MD, PhD, is an active member of the European Society for Medical Oncology and the American Society of Clinical Oncology. She is an ad hoc reviewer for various oncology journals. Furthermore, she actively participates in Phase I, II and III studies with new chemotherapy agents in gastrointestinal tumors. She is specialized in translational research on hepatobiliopancreatic tumors and targeted therapies such as EGFR inhibitors.
